SCHEMBL24933256

SCHEMBL24933256

NC(=O)c1cc(-c2ccc(OCCO)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.43
CHEK2 O96017 2/20 0.42
PARP1 P09874 2/20 0.41
PRKAB2 O43741 3/20 0.39
PRKAG1 P54619 3/20 0.39
PRKAA2 P54646 3/20 0.39
PRKAA1 Q13131 3/20 0.39
PRKAG3 Q9UGI9 3/20 0.39
PRKAG2 Q9UGJ0 3/20 0.39
PRKAB1 Q9Y478 3/20 0.39
FFAR4 Q5NUL3 3/20 0.39
XDH P47989 2/20 0.38
HSD17B1 P14061 4/20 0.38
HSD17B2 P37059 4/20 0.38
MOGAT2 Q3SYC2 2/20 0.37
FFAR1 O14842 2/20 0.37
BRD4 O60885 1/20 0.36
BRD1 O95696 1/20 0.36
BRD2 P25440 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933847 0.91 CHEK1 (0.46) CHEK2PARP1PRKAB2PRKAG1PRKAA2
SCHEMBL24933416 0.89 HSD17B1 (0.36) PDK2CHEK2PARP1FFAR4HSD17B1
SCHEMBL24933007 0.88 PPARD (0.44) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24932951 0.88 CHEK1 (0.48) PDK2CHEK2PARP1MOGAT2
SCHEMBL24933418 0.88 MOGAT2 (0.41) PDK2CHEK2PARP1FFAR4XDH
SCHEMBL24932956 0.87 FYN (0.45) CHEK2PARP1HSD17B1HSD17B2BRD4
SCHEMBL24933213 0.87 MAOB (0.36) PDK2CHEK2PARP1PRKAB2PRKAG1
SCHEMBL24933349 0.85 GSTP1 (0.50) CHEK2XDHHSD17B1HSD17B2FFAR1
SCHEMBL24933053 0.85 KDM4E (0.44) PARP1HSD17B1HSD17B2CYP2C9
SCHEMBL30240692 0.83 MAOB (0.46) PARP1FFAR1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed